Catalent Enters Into Commerical Supply Agreement with Vivus for Qsymia™ Once-Daily Combination Extended-Release Capsules
Somerset, NJ, October 1, 2012 - Catalent Pharma Solutions announced that it has entered into a Supply Agreement with VIVUS, Inc. to supply Qsymia™ capsules, a proprietary combination phentermine and extended-release topiramate. Utilizing its unique drug delivery capabilities, Catalent partnered with VIVUS during the development of Qsymia, including pre-formulation and formulation, clinical supply and validation.
Qsymia has recently been approved by the FDA as the first once-daily combination treatment for chronic weight management in adults who are obese or overweight with a weight-related co-morbidity.
“It is extremely exciting for Catalent to see the FDA approval of this significant new therapy for weight management. As a combination therapy with two active ingredients that needed to be formulated and delivered in a controlled release dosage form, Qsymia presented unique formulation and drug delivery challenges. We are very pleased to have partnered with VIVUS in developing Qsymia and look forward to a long and successful relationship,” commented Dr. Ian Muir, President of Catalent’s Modified Release Technologies business.
Peter Tam President of VIVUS added, “An extended release formulation of Qsymia was critical to achieving our aim of developing a once-daily treatment. Catalent’s broad range of drug delivery capabilities and extensive experience in controlled-release technologies helped us to achieve our goal. VIVUS is also pleased to have completed a long-term commercial supply agreement with Catalent to ensure the reliable on-going supply of Qsymia.”
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J.
more products. better treatments. reliably supplied.™